Inhibikase Therapeutics (IKT)
(Delayed Data from NSDQ)
$1.39 USD
-0.08 (-5.44%)
Updated May 1, 2024 10:24 AM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Inhibikase Therapeutics, Inc. [IKT]
Reports for Purchase
Showing records 1 - 12 ( 12 total )
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Update on Phase 2 201 Trial For Risvodetinib Expected at AD/PD Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Outcomes of Pre-NDA Meeting With the FDA for IkT-001Pro
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Risvodetinib (IkT-148009) Receives Orphan Drug Designation For the Treatment of Multiple System Atrophy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Data Announced From 501 Bioequivalence Trial of IkT-001Pro
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
2Q23 Results; Enrollment Ongoing in Phase 2 Trial For IKT-148009 in Parkinson''s Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
1Q23 Results; First Patient Dosed in Phase 2a Trial in Parkinson''s Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
1Q23 Results; First Patient Dosed in Phase 2a Trial in Parkinson''s Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Positive Updates in IkT-148009 Development in Parkinson''s Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Moving Forward With a Novel Treatment Candidate for Parkinson''s Disease; Initiating Coverage With a Buy Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
|